Successfully navigating the Euro-5 orphan drug markets requires a deep understanding of country-specific market access frameworks, HTA evidence requirements, pricing and reimbursement mechanisms, and rare disease healthcare ecosystems
Our new position paper provides a country-specific assessment of France, Germany, Italy, Spain and the UK / England, highlighting national frameworks and their implications for pharmaceutical companies
